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Biological Therapy in the 
Prevention of Complications 
of Crohn
Dolores Ortiz-Masià
Abstract
In recent years, the advent of biological agents has revolutionized the treatment 
of inflammatory bowel disease (IBD). TNF is a cytokine with a very important role in 
the pathogenesis of Crohn’s disease (CD), so it is a therapeutic target to highlight. The 
efficacy and safety of the anti-TNF, IFX and ADA is widely established, becoming two 
of the therapeutic pillars of CD. Today the experience with other more recent antibod-
ies and stem cells therapy is more limited. Various limitations such as lack of studies, 
heterogeneity in inclusion criteria, and achievement of objectives make it difficult to 
establish which treatment is more appropriate in each case and even the superiority 
between drugs and/or cellular therapy. This chapter will compare the different cur-
rently available therapies with special interest in new therapies and their relationship 
in the prevention of complications of Crohn’s disease.
Keywords: Crohn’s disease, fibrosis, inflammation, biological therapy, inflammatory 
bowel disease, stem cells
1. Introduction
Acute inflammatory processes affecting the intestine are relatively frequent 
and self-limiting, such that the intestinal mucosa is able to regenerate and regain 
homeostasis in a matter of days. However, chronic inflammation can cause irrevers-
ible structural changes and severe complications in the gastrointestinal tract [1].
The term inflammatory bowel disease (IBD) is used to refer generically to 
chronic inflammatory diseases, with recurrent course and unknown origin that 
affect the gastrointestinal tract and are distinguished mainly on the basis of histo-
logical findings. Basically in this group we find Crohn’s disease (CD) and ulcerative 
colitis (UC), processes that have their peak incidence in young people and that 
constitute the most relevant pathologies within this classification. These patholo-
gies are identified and diagnosed thanks to clinical, endoscopic, and histological 
characteristics, although on certain occasions it is not possible to distinguish which 
form of IBD is present, being classified as indeterminate colitis. Microscopic 
colitis is a term designated for a group of colitis in which we find microscopic but 
not macroscopic alterations when endoscopy or surgery is performed. Unlike the 
previous ones, this process mainly affects elderly people and includes collagenous 
colitis and lymphocytic colitis. Despite having similar epidemiological, clinical, and 
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even therapeutic characteristics, there are a series of peculiarities that help to define 
the existing process [2]. CD is characterized by the existence of transmural inflam-
mation, cryptic abscesses, and the formation of granulomas, being able to affect 
any part of the intestine and may reappear after surgical resection of the affected 
segment [3]. UC, on the other hand, is typically associated with inflammation and 
ulceration limited to the mucosa and submucosa, only of the colon and rectum. In 
this way, and unlike CD, UC has a definitive treatment of the pathology in procto-
colectomy. The main differential characteristics between CD and UC are shown in 
Table 1. The incidence of both diseases is increasing in the last decades and in the 
case of CD at younger ages [4].
Current CD therapies are solely targeting inflammation by administration of 
immunosuppressive therapies, corticosteroids, or biologicals. While these thera-
pies in some—but not all—cases lead to symptomatic disease remission, recurrent 
flares interspaced with periods of remission will still result in cumulative gut wall 
remodeling. The evolution towards organ failure and surgical resection occurs in 
70% of cases, with a subsequent need of second surgery in up to 30% of cases [5]. 
The postsurgical recurrence can occur very early, even a few weeks after surgical 
Characteristics Crohn’s disease Ulcerative colitis
Macroscopic
Intestinal region Ileum ± colon Colon
Distribution Sautéed lesions Diffuse lesions
Stenosis Yes No
Wall appearance Thick Thin
Microscopic
Inflammation Transmural Limited to mucosa
Pseudopolyps Moderate Important
Ulcers Depths Superficial
Lymphoid reaction Important Moderate
Fibrosis Important Mild or absent
Serositis Important Mild or absent
Granulomas Yes No
Fistulas Yes No
Clinics
Rectal involvement Frequent Almost always
Small bowel involvement Frequent Rare
Perianal fistula Yes No
Malabsorption of fats and vitamins Yes No
Malignant potential Affecting the colon Yes
Relapses after surgery Frequent No
Toxic megacolon No Yes
pANCA + ++
ASCA ++ +
The table shows the main macroscopic, microscopic, and clinical characteristics between CD and UC.
Table 1. 
Differential characteristics between CD and UC.
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resection, because the drugs currently available for the prevention of postsurgical 
recurrence have limited efficacy; up to 50% of cases return to CD activity despite 
preventive treatment, which may lead to further surgery with consequent loss 
of bowel function which may eventually lead to the development of short bowel 
syndrome as an irreversible complication in some patients. Therefore, manage-
ment of CD patients undergoing bowel resection should be oriented towards 
prevention, early detection, and, in the worst case, treatment of postsurgical 
recurrence [6].
Given the great evolution experienced in IBD therapy, there is a need to compare 
the effectiveness of different treatments in the achievement of objectives as well as 
a clear definition of the objectives. The symptoms, although an indicator of quality 
of life, have a very poor correlation with the severity of inflammation. On the other 
hand, endoscopic activity, serological markers, and fecal calprotectin have greater 
correlation with the future need for surgery and occurrence of complications.
Among the objectives of the therapeutics of IBD, we highlight the induction of 
remission, the reduction of hospitalizations and surgeries, and the effectiveness of 
cellular therapy in fistulizing and luminal disease.
The general objective of this chapter is to address this gap in literature by 
reviewing bibliography comparing the different biological therapies available and 
their influence on the prevention of complications.
2. Crohn’s disease
CD is a chronic, recurrent inflammatory disease that belongs to the spectrum of 
IBD. It predominantly affects the gastrointestinal tract, being able to find lesions in 
any part of it, from the mouth to the anus. In it we also find important extraintes-
tinal manifestations and association with other autoimmune diseases [7]. CD is an 
entity whose incidence increases as the development of society advances, being very 
prevalent in developed countries and rare in less developed countries.
The maximum incidence is observed between the second and fourth decade of 
life, and a second peak is observed between the seventh and ninth, although it is 
increasingly diagnosed at earlier ages [4].
2.1 Etiopathogenesis
Although several factors have been described that may be related to the develop-
ment of CD, the exact causes of this process remain unknown (see Table 2).
Genetics Seventy-one susceptibility locus for CD have been identified on 17 
chromosomes
Environmental factors Non-breastfeeding, improved hygiene conditions, sedentary lifestyles, western 
diet and fast food, tobacco, contraceptives, environmental pollution
Microbiota Reduction of commensal microbiota: Bacteroidetes and Firmicutes
Increase in potentially pathogenic flora: Mycobacterium avium paratuberculosis, 
Campylobacter, Salmonella, and E. coli
Alteration of the 
immune system
Deregulation in the immune system that initiates, mediates, and perpetuates 
inflammation. Rapid recruitment and inappropriate accumulation of 
leukocytes in the affected intestinal wall
The table shows the main causes of CD.
Table 2. 
Etiopathogenesis of CD.
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Several studies [8, 9] have found different genetic alterations that increase 
susceptibility to this disease along with certain environmental triggers, resulting in 
an altered immune response, both innate and adaptive, and epithelial bowel dys-
function. An alteration in the commensal microbiota has also been described, with 
a decrease in the potentially beneficial flora and an increase in that which is poten-
tially pathogenic [8]. Genetic alterations, the immune system, microbiota, environ-
mental factors, and their combined effects occupy a large number of pages in the 
scientific literature, and their description surpasses the objectives of this study.
2.2 Symptoms, diagnosis, and classification
CD is a heterogeneous entity comprising different phenotypes, so the symptoms 
are and change with the course of the disease. It usually has an insidious onset, the 
most common symptom being chronic diarrhea (80% of patients), followed by 
abdominal pain (70%), primarily in the right iliac fossa.
Other symptoms are weight loss (50%), malnutrition, fatigue, malaise, and the 
presence of rectorrhagia (more common in UC). Perianal disease (4–10% debut with 
it), nausea, vomiting, asthenia, anorexia, fever, and night sweats may also occur.
Diagnosis is currently established by combining clinical presentation and 
laboratory findings (such as anemia, elevation of globular sedimentation velocity 
and serum C-reactive protein, elevation of calprotectin and/or lactoferrin in stool, 
endoscopic appearance, histology, and radiological and/or biochemical findings). 
Serological and genetic tests are not recommended as routine diagnostic methods. 
However, despite advances in diagnostic methods, in the first year, up to 5% of cases 
with the diagnosis of CD has to be changed to UC or indeterminate colitis [10].
Once the diagnosis of CD is established, it is necessary to categorize patients 
based on the Montreal classification [11] and investigate the possible existence of 
extraintestinal manifestations and other autoimmune diseases (see Table 3). This 
stratification of patients makes it easier for them to receive the best follow-up and 
treatment in an individualized manner as well as to identify early possible compli-
cations [12]. However, it is important to bear in mind that the patient’s stratification 
is not stable. It has been seen that 19% of patients progress to more aggressive forms 
of the disease 90 days after being staged and up to 51% of patients did so 20 years 
after the initial diagnosis [12]. These patients progressed developing complications 
that were not present at the time of diagnosis.
Age at diagnosis A1:<16 years
A2:17–40 years
A3:>40 years
Location L1:terminal ileum
L2:colonic
L3:ileocolon
L4:upper gastrointestinal tract
Behavior B1:without stricture formation, non-penetrating
B2:stenosant
B3:penetrating
P:perianal disease
Table 3. 
CD Montreal classification [11].
5Biological Therapy in the Prevention of Complications of Crohn
DOI: http://dx.doi.org/10.5772/intechopen.90557
Complications depend on the clinical course and control of the disease. Some 
may appear in any phenotype, such as massive hemorrhage, toxic megacolon, and 
neoplasia of the colon (the IBD favors the presence of multiple tumors with a higher 
degree of malignancy), while other complications are encompassed in different 
phenotypes of the disease. Thus, in the obstructive fibro-stenotic pattern, we 
find stenosis, intestinal obstruction, and perianal disease; and in the penetrating, 
fistulas and abscesses.
Most complications require a surgical approach; in fact, 70–80% of patients with 
CD will need some surgery throughout their lives. Even so, there are recurrences in 
88% of the cases, being very frequent the surgical reintervention.
2.3 Treatment
There are currently multiple drugs available for the treatment of IBD; however, 
there are no predictive response factors that allow us to select the most appropriate 
drug for a patient at any given time. In general, the choice of treatment is made 
on an individual basis according to the activity, location, and phenotype of the 
affectation.
The objectives include symptomatic control, remission of the outbreak and 
maintenance of long-term remission, as well as endoscopic healing, as there is no 
curative treatment. The drugs used are:
• Aminosalicylates: indicated as maintenance treatment in mild to moderate 
CD. They include those molecules with aminosalicylic acid or 5-ASA in their 
molecular structure (also known as mesalazine in Europe and mesalamine in 
the USA). They have been shown to reduce the incidence of relapses (28 versus 
55% with placebo) and have a higher percentage of remissions versus placebo 
(43 versus 18%, respectively). However, the efficacy in postoperative patients 
is greater. In general, they are well tolerated, and adverse effects such as 
gastrointestinal disorders, headache, arthralgias, and cutaneous eruptions may 
appear. The nephrotoxicity and hematological toxicity are the more serious, 
but infrequent, effects [13, 14].
• Glucocorticoids: indicated for the induction of remission in an outbreak. They 
intervene on the vascular [decreasing permeability] and cellular [inhibiting 
tissue migration and phagocytosis of macrophages] phases. Prednisone is usu-
ally used at a dose of 40–60 mg/day orally or intravenously in severe outbreaks 
(with remission rates of 66–73%). Budesonide has shown similar efficacy to 
prednisone for mild to moderate ileocolonic CD (55% remissions). In addition, 
its topical action confers fewer adverse effects. However, they have not shown 
efficacy as a therapy for maintenance. In addition, this would be inadvisable 
given the risk of dependence and adverse effects: fluid retention, stretch 
marks, redistribution of body fat, subcapsular cataracts, myopathy, osteone-
crosis, emotional disturbances, withdrawal symptoms, etc., many of which are 
related to the duration of treatment [15, 16].
• Antibiotics: have no role in the treatment of CD, except metronidazole in 
perianal disease.
• Thiopurines: azathioprine (AZA) and 6-mercaptopurine (6MP). They are 
used in the management of corticosteroid-dependent CD, in the prevention 
of postsurgical recurrence, and in combination with biologics. The efficacy 
is appreciated from 3 to 4 weeks both as maintenance therapy and in perianal 
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disease. They present a great interindividual variability, due to the genetic 
polymorphisms of TPMT (thiopurine methyltransferase), an enzyme that 
activates them. In general they are well tolerated, being hepatotoxicity, myelo-
toxicity and pancreatitis acute, the adverse effects to highlight, able to justify 
abandonment of the treatment. Other effects are nausea, fever, skin rash, 
hepatitis, and the development of lymphomas.
• Methotrexate: inhibitor of dihydrofolate reductase (folic acid antagonist). It 
is effective in maintenance of remission (65 versus 39% with placebo), with 
an evaluation necessary of hepatic enzymes. Hypersensitivity pneumonitis 
is a very rare but very serious adverse effect. Supplementation with folic acid 
reduces adverse effects. It is a teratogenic drug, so it is contraindicated during 
pregnancy and lactation [17].
• Calcineurinics: cyclosporine (CyA) and tacrolimus. Its usefulness is limited, 
although tacrolimus seems useful in perianal EC. CyA has a series of cases that 
support it in luminal and perianal EC, but the evidence is not robust.
• Hematopoietic stem cell transplantation (HSCT): might be useful in some 
treatment-resistant cases. Mesenchymal stem cells (MSCs) have regenerative 
and immunomodulatory properties which lead to reduction of inflammation 
and healing of affected intestinal tissue in CD. Meta-analysis studies show that 
23–40.5% of patients achieved remission after systemic infusion of MSCs [18, 19].
• Monoclonal antibodies: include the anti-TNF and anti-integrin α4β7, which we 
will discuss with more depth below.
3. Biological therapy in CD
Biologic therapy was introduced as a treatment for CD 20 years ago, revolution-
izing the handling of it. So far, infliximab (IFX), adalimumab (ADA), vedolizumab 
(VDZ), and ustekinumab have been approved in Europe for this purpose. In general 
they have a good safety profile, although the experience is limited in new drugs.
They have been shown to be effective in decreasing intestinal damage from 
inflammation, surgeries, and admissions, improving the quality of life of patients. 
Its benefits, specially their early administracion as well as their favorable safety 
profile, have meant that they are being used more and more frequently.
It should be noted that before starting treatment with biological therapy, it 
is necessary to rule out an active infection (mainly tuberculosis or hepatitis B). 
In addition, the appearance of hypersensitivity reactions, cutaneous reactions, 
cytopenias, heart failure, and autoimmune hepatitis forces to rule them out and 
assess a possible interruption of treatment. Its paradoxical inflammatory reactions 
have been described with psoriasis and dermatitis, which can affect even 10% of 
patients. Treatment with biologics contraindicates attenuated vaccines.
Its potential adverse effects make it necessary to stratify the patients, so that only 
those with severe or complicated illness receive early intensive therapy. Although 
there is no established definition of serious or complicated disease, greater com-
plications are seen in patients who start the disease young (<40 years), perianal 
disease and/or ileocolic localization, with need to administer corticosteroids in 
the treatment of the first outbreak, in these cases. When two or more factors are 
present, it is indicated to start the treatment of the first outbreak with immuno-
modulators or biologicals. Various studies support that, although the monoclonal 
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antibodies are more expensive than other treatments, the decrease in the number of 
hospitalizations and surgeries contributes to increase the cost/benefit ration of the 
therapy, especially as a therapy of the maintenance.
3.1 Anti-TNF
Anti-TNFs are so far the most effective agents in the treatment of moderate-
to-severe luminal disease (induction of remission and maintenance) and Crohn’s 
fistulizer, and they are the first-line treatment in complex perianal disease. In 
Europe, IFX and ADA are approved in EC and CU and golimumab in CU. The 
results obtained have raised treatment expectations, with healing of the mucosa 
being the main objective, associated with a lower rate of hospitalizations and 
surgery and with a higher percentage of long-term remission. Difficulty in selecting 
patients that are going to benefit from these treatments lies in safety problems (risk 
of infections, infections, etc.) and its high cost.
Anti-TNFs have demonstrated a good safety profile, the main drawback being 
the risk of infections, such as tuberculosis, pneumocystis, and nocardiosis. More 
than half of infections occur in the first 6 months of treatment and in guidelines 
combined with immunosuppressants. All of these risks justify the recommendation 
to update the vaccination schedule before starting treatment, as well as screening 
for latent infections [20].
The increased risk of cancer is controversial in the literature. A meta-analysis that 
included 12 cohort studies concluded that although the risk of melanoma is increased 
by 37% in patients with IBD, treatment with anti-TNF did not influence it [21].
Less frequently, they have also been associated with optic neuritis, seizures, and 
demyelinating disorders, including multiple sclerosis and exacerbation of heart 
failure symptoms grade III/IV. Adverse effects make it necessary to discontinue 
treatment in 20.6% of patients with IFX and 14.4% with ADA [22–25].
Another aspect to mention is the lack of effect (30%) and the loss of therapeutic 
efficacy, which occurs in 23–26% of patients in the first 12 months of treatment. 
The causes are varied: in some patients there is a pharmacodynamic failure, when 
the main pathway of inflammation is not dependent on TNF. Others do not get a 
good pharmacokinetics, when the concentrations in plasma are insufficient, due to 
increased clearance or appearance of anti-drug antibodies.
There is evidence that good plasma levels of anti-TNF are associated with greater 
clinical efficacy, so monitoring of antibody levels has become a tool to optimize the 
treatment. They appear more frequently in patients treated sporadically than those 
treated every 8 weeks. In these situations, it is possible to add immunosuppressants 
(AZA, 6-MP, or methotrexate).
3.2 Anti-integrin α4β7
Until 2015, anti-TNFs were the only biologicals approved for the treatment of 
IBD in Europe. This year anti-integrin α4β7 antibodies were incorporated: vedoli-
zumab (VDZ) and ustekinumab. In general, they present an acceptable safety 
profile, as no case of leukoencephalopathy has been recorded to be progressive 
multifocal, its most fearsome adverse effect. As for the rest of the adverse effects, 
specific monitoring is not required.
Vedolizumab is a recombinant humanized IgG1 AcM that specifically blocks 
the integrin α4β7 by joining MadCAM-1. It has recently been approved for EC 
and moderate-to-severe CU that have failed conventional treatment but also as a 
first-line drug. It is administered via IV, for which it has demonstrated efficacy in 
inducing remission and maintaining disease, the maintenance in postoperatives 
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being its main indication. It has been postulated that its answer is slower because 
it does not block the pre-existing inflammation; it simply avoids recruiting more 
inflammatory cells. In addition, transmural involvement of CD may explain its 
action to be slower than CU.
The induction dose is 300 mg IV in weeks 0, 2, and 6, followed by 300 mg every 
8 weeks as maintenance. A long-term loss of response has been noted, although usu-
ally in patients who have already failed other biologics. VDZ is a well-tolerated drug 
with a good security profile in IBD. The risk of infections increases but no cases of 
progressive multifocal leukoencephalopathy (PML), and the frequency of transfu-
sion reactions is lower than that of the 5%. The development of anti-VZD antibodies 
occurred in less than 4% of patients, being a cause of therapeutic failure [26].
Natalizumab is a humanized IgG4 against the subunit α4, so it blocks both the 
integrin α4β7 and integrin α4β1; it therefore, has a non-specific action. It has shown 
promising results as maintenance therapy but has not been approved by its associa-
tion with cases of progressive multifocal leukoencephalopathy. It is approved for CD 
in the USA under very severe conditions (concomitance with multiple sclerosis).
3.3 IL-12 and/or IL-23 inhibitors
IL-12 and IL-23 have been shown to be key cytokines in the adaptive immunity, 
which is found in IBD and intervenes in its chronification. Both ILs have in common 
the subunit p40, whose blocking inhibits the intracellular signaling cascade. The 
Crohn’s immune response is influenced by resident lymphocytes and those recruited 
into the lymphoid organs. Antibodies from this group, such as the ustekinumab, 
prevent the binding of soluble IL-12 and IL-23 to their specific receptors, although 
they do not intervene on cytokines that are already attached to their membrane 
receptor. The blockage of IL-12 prevents the activation of Th1 lymphocytes, and 
IL-23 prevents the production of IFNγ, TNFα, IL-1β, and IL-6.
3.4 Sphingosine receptor modulators
Sphingosine-1 is a phospholipid that binds to specific receptors (S1P1–5) 
expressed in lymphocytes, dendritic cells, cardiomyocytes, and endothelial cells, 
regulating multiple cellular activities such as growth and survival, vascular integ-
rity, and lymphocytic migration.
Sphingosine modulators behave like agonists producing functional antagonism, 
sequestering lymphocytes in peripheral lymphoid organs, and reinforcing the 
endothelial barrier (which makes intestinal migration difficult) [27].
3.5 JAK kinase inhibitors
Protein kinases are enzymes capable of modifying other proteins or enzymes, 
altering their function depending on the target. Certain polymorphisms of the 
same ones have been related with greater susceptibility to IBD. The signaling of this 
group of drugs is very complex, but it is a promising research in the field of IBD 
therapy (currently in phase 3 for both UC and CD).
In its mechanism of action, B lymphocytes and T effectors decrease without 
affecting the T regulators.
3.6 Biological therapy in the induction of remission
We speak of partial or total remission to refer to the reduction or disappearance 
of symptoms and signs of disease.
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The effectiveness of biological therapy in the induction of remission is indisput-
able. However, the percentages vary considerably between different molecules. At 
week 4, remission rates reach 75% with IFX [28] and 59% with ADA [29].
The study PRECISE 1 investigated the effects of CTZ at week 6 and shows remis-
sion rates of 37% with CTZ and 31.4% for VDZ [30]. Clearly higher percentages are 
noticeable with IFX and ADA.
Considering luminal disease, remission rates have been described as 63.8 and 
54.1% for IFX and ADA, respectively, and remission in cortico-dependent patients 
as 76.3 and 44.7% for IFX and ADA at 12 months. Combination with immunosup-
pressants led to higher remission rates in patients with IFX (81 versus 52%), but not 
in ADA [31].
In general, IFX is given to patients with a more severe phenotype of the disease, 
as it is believed to have faster action and more clinical experience. However, the 
results were similar in patients who received IFX and ADA, without finding signifi-
cant differences in Crohn naïve patients except in the safety profile (adverse effects 
were more frequent with IFX than with ADA, 36.1 versus 15.5%, respectively), 
including transfusion reactions, skin rashes, arthralgias, and hypersensitivity [31]. 
This information is contradicted by other studies, such as the meta-analysis of 
Singh and collaborators, whose results support the superiority of IFX over the rest 
of the biologics for induction of clinical remission in naïve anti-TNF patients [32].
3.7  Impact of biological therapy in the prevention of complications of  
Crohn’s disease
The effectiveness of biological therapy in the prevention of hospitalizations and 
surgeries has not yet been clearly demonstrated. We know from previous stud-
ies that in the prebiological era, approximately 50% of patients required surgery 
10 years after diagnosis, with a risk of recurrence of 50% at 10 years, and 80% of 
patients required surgery at some point in their lives. Recent studies indicate that 
surgery rates since the introduction of biologics (2001–2008) are lower than those 
of 1988. In addition, a very relevant characteristic of biologics is their high cost, and 
it is here that the reduction of the overall cost through the prevention of complica-
tions becomes especially important [33, 34].
The anti-TNF therapy reduces significantly the hospitalizations and surgeries 
in patients with CD. No differences were observed between IFX and ADA, with a 
reduction of 46% (36–60%) of the hospitalizations and 13–42% of surgery with 
IFX. The onset of treatment may also be relevant in modifying the natural history 
of the disease. In this line, it has noted that early use of biological therapy (less than 
2 years after diagnosis) improves the course of the disease. However, no significant 
reduction in the number of surgeries has been found in hospitalizations with 
patients treated with VDZ or AZA in similar follow-up periods [33].
4. Hematopoietic stem cell transplantation
Human stem cell therapy for the treatment of CD is still in its infancy, and 
whether SCT is associated with improved outcomes is unclear.
Preliminary studies have shown that allogeneic HSCT may restore, at a genetic 
level, the immune system [35, 36], and autologous HSCT could remove atypical 
clones by immunoablation and replacement with not committed stem cells (SCs), 
allowing for the de novo generation of an altered T-cell repertoire [37]. Some stud-
ies describe that autologous and allogeneic HSCT produce a long-term treatment-
free disease regression in some patients with CD [19]. Nevertheless, the Autologous 
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Stem Cell Transplantation International Crohn’s Disease Trial [38] did not validate 
a statistically significant improvement in continued disease remission at 1 year of 
autologous HSCT compared with orthodox therapy, suggesting that further studies 
are needed in order to know the feasibility of using HSCT in patients with refrac-
tory CD [19].
4.1 Luminal disease
The number of patients requiring surgical resection for the stenosing and 
uncontrolled inflammatory complications of CD has not declined significantly, 
despite advances in biological therapy. Moreover, following a surgical resection, 
many patients will require a second operation. Currently, the use of systemically 
infused mesenchymal stem cell to reduce the altered inflammatory response and 
to repair impaired tissue has a promising future for avoiding surgery and its poten-
tially serious complications. Conversely, since biological therapies are not always 
useful in some patients, the development of all-purpose anti-inflammatory thera-
pies for patients with inflammatory luminal disease is still needed.
In luminal disease, the mechanism of the intravenous transplantation of MSCs 
is not understood yet. Animal studies and graft-versus-host disease treated by 
bone marrow MSC studies suggest, on the one hand, that the MSCs are able to 
transmigrate from the circulation into the inflamed tissues as a response to cytokine 
stimulus; on the other hand, MSC can release anti-inflammatory cytokines, which 
can modify the phenotype of macrophages towards repairing phenotype and can 
mediate the activation and proliferation of regulatory T and B cells.
One study that demonstrated the safety and viability of MSC in luminal disease 
was evaluated in nine patients with refractory CD, where the patients received two 
infusions of autologous bone marrow-derived MSC (days 0 and 7). At 6 weeks, 
endoscopic improvement was reported in two patients and clinical improvement 
in three, while three patients required surgery due to worsening disease [39]. In the 
same line, similar results were also seen in 15 CD patients with moderate-to-severe 
active disease who were refractory to anti-TNFα therapy [40]. In that study, at 
6 weeks, a clinical response was observed in 80% of patients, clinical remission in 
53% of patients, and endoscopic improvement in 47% of patients [40].
Evidence that MSC therapy contributes to neoplastic development is currently 
lacking. However, this view is based on a systematic review in which not all patients 
were assessed by repeated endoscopy during the 10-year follow-up, so the presence 
of dysplastic lesions cannot be excluded [19]. New and better studies are needed to 
test the safety of MSC therapy in luminal disease.
4.2 Fistulizing disease
Fistulae commonly complicate CD. There has been more research on the 
efficacy of MSC therapy in perianal fistulizing CD than on luminal CD. In all 
cases, the reduction of fistula frequency and the improved rate of complete 
fistula closure are the most important therapeutic goals. Administration of the 
therapeutic agent is performed locally under general anesthesia during peri-
anal surgery. In the intervention, the surgeon initially scans the fistula tracts 
to remove setons and residual inflamed tissues. Once the internal opening is 
sealed with absorbing suture, the submucosa surrounding the internal orifices 
of fistulas and parallel to the lumen of tracts receives an injection of MSCs. The 
difference between results depends on different parameters like used dosage, 
origin and type of MSCs, therapeutic schedules, definition of end points, and 
therapeutic efficacy.
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The safety and therapeutic potential of MSCs in treating perianal CD was first 
demonstrated in 2005 when autologous adipose-derived MSC was injected into nine 
perianal fistulae from four patients. After 8 weeks, complete healing was observed 
in six fistulae [41]. Fistula tract healing has been observed in 71% of patients treated 
with MSC and fibrin glue as compared to 16% of patients treated with fibrin glue 
alone. In patients receiving MSCs, closure was observed in 46% of patients after a 
single treatment and in a further 25% after a second rescue treatment [42, 43].
The currently available largest randomized, double-blind placebo-controlled 
study summarizes the clinical data of fistulizing CD patients which show that a 
greater proportion of patients in the treated group than the placebo group achieved 
the combined remission at week 24 in the intent-to-treat population (53 of 103 
(51%) vs. 36 of 101 (34%)) [44].
5. Conclusions
• The evidence places IFX over the rest of the biologics in the induction of remis-
sion in patients with naïve CD. It has shown higher remission percentages in 
numerous quality studies and in direct meta-analysis comparisons. While this 
information is contradicted by other articles, IFX seems to be more effective 
and faster acting, so it is the preferred biological therapy in patients with 
severe disease. In addition, it is the only one that has proven to be more effec-
tive in combination with immunosuppressants.
• The biological treatments are the only ones that have shown effectiveness in 
the reduction of hospitalizations and surgeries. A number of studies have high-
lighted the superiority of IFX over other biologicals, as well as the equivalence 
between ADA and CTZ.
• Clinical trials demonstrated that MSC transplantation has an outstanding, 
durable efficacy with low fistula recurrence in biological therapy-refractory 
fistulizing CD; however, further clinical trials are required to confirm its 
effectiveness in luminal CD.
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